ORAGENICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences
ORAGENICS, INC. (OGEN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences of $8.75 thousand as of 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences · last filed 2024-03-29
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $8.75K.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $19.45K.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $41.36K.
- 2019-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences $35.93K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences |
|---|---|
| 2022-12-31 | $8.75K 10-K · filed 2024-03-29 |
| 2021-12-31 | $19.45K 10-K · filed 2023-04-17 |
| 2020-12-31 | $41.36K 10-K/A · filed 2022-07-29 |
| 2019-12-31 | $35.93K 10-K · filed 2021-03-01 |
| 2018-12-31 | $30.05K 10-K · filed 2020-03-04 |
| 2017-12-31 | $26.29K 10-K · filed 2019-03-29 |
| 2016-12-31 | $35.13K 10-K · filed 2018-02-16 |
| 2015-12-31 | $33.90K 10-K · filed 2017-02-27 |
| 2014-12-31 | $29.27K 10-K · filed 2016-03-30 |
| 2013-12-31 | $32.10K 10-K · filed 2015-02-27 |
| 2012-12-31 | $20.34K 10-K · filed 2014-02-28 |
| 2011-12-31 | $32.23K 10-K · filed 2013-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |